We used propranolol, a widely applicable cardiovascular drug that has been utilized to antagonize the β-adrenergic receptor for more than 50 years [23], to explore the antitumor property of combining it with VEGFR2-TKIs in NSCLC. The gene discussed is KDR; the disease is non-small cell lung carcinoma.